Dapagliflozin: A guide to its use in type 2 diabetes mellitus

被引：0
作者：
Hines M. [1 ]
Lyseng-Williamson K.A. [1 ]
Plosker G.L. [1 ]
机构：
[1] Adis, North-Shore 0754, Auckland, 41 Centorian Drive, Mairangi Bay
来源：
Drugs & Therapy Perspectives | 2013年 / 29卷 / 7期
关键词：
Metformin; Glycaemic Control; Glimepiride; Glipizide; Hypoglycaemic Event;
D O I：
10.1007/s40267-013-0045-9
中图分类号：
学科分类号：
摘要：
Dapagliflozin (Forxiga®), the first available renal sodium-glucose co-transporter-2 inhibitor, is a glucose-lowering agent with a unique insulin-independent mechanism of action. Relative to placebo, oral dapagliflozin significantly reduced glycated haemoglobin and fasting plasma glucose values when administered as monotherapy in previously untreated patients with type 2 diabetes mellitus, and as add-on therapy in patients with inadequately controlled type 2 diabetes despite treatment with oral antidiabetic agents or insulin-based therapy. Dapagliflozin is generally well tolerated with a low propensity to cause hypoglycaemia. © 2013 Springer International Publishing Switzerland.
引用
收藏
页码：194 / 199
页数：5
相关论文
共 22 条
  • [1] Inzucchi S.E., Bergenstal R.M., Buse J.B., Et al., Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 35, 6, pp. 1364-1379, (2012)
  • [2] Standards of medical care in diabetes: 2012, Diabetes Care, 35, SUPPL. 1, (2012)
  • [3] Plosker G.L., Dapagliflozin: A review of its use in type 2 diabetes mellitus, Drugs, 72, 17, pp. 2289-2312, (2012)
  • [4] Ong K.L., Cheung B.M., Wong L.Y., Et al., Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004, Ann Epidemiol, 18, 3, pp. 222-229, (2008)
  • [5] Nair S., Wilding J.P., Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus, J Clin Endocrinol Metab, 95, 1, pp. 34-42, (2010)
  • [6] Neumiller J.J., White Jr.J.R., Campbell R.K., Sodium-glucose co-transport inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus, Drugs, 70, 4, pp. 377-385, (2010)
  • [7] Summary of Product Characteristics, (2012)
  • [8] Ferrannini E., Ramos S.J., Salsali A., Et al., Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial, Diabetes Care, 33, 10, pp. 2217-2224, (2010)
  • [9] Bailey C.J., Gross J.L., Pieters A., Et al., Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial, Lancet, 375, 9733, pp. 2223-2233, (2010)
  • [10] Strojek K., Yoon K.H., Hruba V., Et al., Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial, Diabetes Obes Metab, 13, 10, pp. 928-938, (2011)
123